• Read more about HIPEC

To collect patient specimens prior to and after HIPEC procedure, along with gastric cancer samples that are from non-HIPEC procedures to test for novel therapeutic additions to the current standard of care procedures. The focus is to find potential targets by studying the characteristics of the disease metastasis which will allow for better treatment options in the future.

Study Number:

HIPEC

Study Status:

Enrolling

Treatment Agent:

Hyperthermic Intraperitoneal Chemotherapy

Resources and Links

National Clinical Trial Identified Number: Not available

Disease:

• Gastric Cancer,
• Peritoneal Metastasis

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Surgical Oncology

• Read more about SourSop

Short Title: Soursop

The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop). The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.

Study Number:

SourSop

Study Status:

Enrolling

Treatment Agent:

Soursop tea

Resources and Links

National Clinical Trial Identified Number: Not available at this time

Disease:

• Acute Myeloid Leukemia ,
• Multiple Myeloma

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Roger K. Strair, MD, PhD

Department:

• Hematology and Medical Oncology

• Read more about EA7211 STRASS II

Short Title: STRASS II

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.

After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.

Standard arm:

• Large en-bloc curative-intent surgery within 4 weeks following randomization- Experimental arm

Experimental arm:

• 3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomization:

  • High grade LPS: ADM (doxorubicin) 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m3 Q3 weeks.
  • LMS: ADM 75 mg/m2 + DTIC (dacarbazine) 1 g/m2 Q3 weeks
• re-assessment of operability
• curative-intent surgery within 3-6 weeks of last cycle of chemotherapy

Study Number:

EA7211

Study Status:

Enrolling

Treatment Agent:

Surgery, Preoperative chemotherapy

Resources and Links

National Clinical Trial Identified Number: NCT04031677

Disease:

• Retroperitoneal Sarcoma,
• Liposarcoma,
• Leiomyosarcoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Madeline B. Torres, MD

• Read more about EvoPAR-Breast01

Short Title: EvoPAR-Breast01

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer. 

Participants will be randomised in a 2:2:1 ratio to one of the following intervention groups:

• Arm 1: saruparib (AZD5305) plus camizestrant
• Arm 2: Physician's choice CDK4/6i plus physician's choice ET
• Arm 3: Physician's choice CDK4/6i plus camizestrant Treatment continues until BICR-confirmed disease progression, unacceptable toxicity occurs, or the participant withdraws consent.

Study Number:

EvoPAR-Breast01

Study Status:

Enrolling

Treatment Agent:

Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane

Resources and Links

National Clinical Trial Identified Number: NCT06380751

Disease:

• Advanced Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Rebecca J. Jaslow, MD

Department:

• Hematology and Medical Oncology

• Read more about GY036

Short Title: GY036

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Study Number:

GY036

Study Status:

Enrolling

Treatment Agent:

Bevacizumab, Olaparib

Resources and Links

National Clinical Trial Identified Number: NCT06580314

Disease:

• Fallopian Tube Endometrioid Adenocarcinoma,
• Fallopian Tube High Grade Serous Adenocarcinoma,
• Ovarian Carcinoma,
• Ovarian High Grade Endometrioid Adenocarcinoma,
• Ovarian High Grade Serous Adenocarcinoma,
• Primary Peritoneal Endometrioid Adenocarcinoma,
• Primary Peritoneal High Grade Serous Adenocarcinoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• David P. Warshal, MD, FACOG

Department:

• Gynecologic Cancer Center

• Read more about IOV-GM1-201

Short Title: IOV-GM1-201

This study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).

Study Number:

IOV-GM1-201

Study Status:

Enrolling

Treatment Agent:

IOV-4001

Resources and Links

National Clinical Trial Identified Number: NCT05361174

Disease:

• Unresectable Melanoma,
• Metastatic Melanoma,
• Stage III Non-small Cell Lung Cancer,
• Stage IV Non-small Cell Lung Cancer

Study Phase:

I/II

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Hematology and Medical Oncology,
• Lung Cancer

• Read more about AHOD2131

Short Title: AHOD2131

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

Please note that this trial is available at Cooper MD Anderson for ages 18-60 only at this time.

Study Number:

AHOD2131

Study Status:

Enrolling

Treatment Agent:

Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Nivolumab, Prednisolone, Prednisone, Procarbazine Hydrochloride, Vinblastine Sulfate, Vincristine Sulfate

Resources and Links

National Clinical Trial Identified Number: NCT05675410

Disease:

• Lugano Classification Limited Stage Hodgkin Lymphoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Sushil Ghimire, MD

Department:

• Hematology and Medical Oncology

• Read more about Miriam Ziegler, MSN, RN

Ms. Ziegler serves as the Assistant Vice President of Nursing Operations, providing oversight of adult Critical Care, Trauma Admitting, Trauma Stepdown, Trauma Med-Surg, Inpatient Oncology, and the Vascular Access team. In this role, she is dedicated to driving operational excellence and advancing quality outcomes across the continuum of care.